Investment Rating - The report maintains a "Buy" rating for the company [1] Core Views - The company is positioned as a leading player in the affordable beverage market, with a focus on high-quality products priced around 6 RMB (approximately 1 USD) [15] - The company has established a robust supply chain and a unique market position through its "high-quality and affordable" brand strategy, which has resonated well with consumers [15] - The report forecasts significant growth in revenue and net profit, with expected net profits of 58.5 billion, 65.2 billion, and 73.0 billion RMB for 2025, 2026, and 2027 respectively, reflecting year-on-year growth rates of 32%, 12%, and 12% [1] Summary by Relevant Sections 1. Company Overview - The company operates over 46,000 stores globally, making it the largest beverage chain in terms of store count, with a product output ranking first in China and second globally [15] - The company has a concentrated ownership structure, with the founders holding 81.14% of shares, which enhances management stability and strategic alignment [24] 2. Business Model - Revenue primarily comes from the sale of goods and equipment to franchisees, with 94% of revenue derived from product sales [33] - The company has a vertically integrated supply chain, allowing for cost advantages and efficient operations, which contribute to a stable gross margin above 30% [34] 3. Market Position and Growth Potential - The affordable beverage segment is expected to continue growing rapidly, driven by increasing consumer demand and market penetration in lower-tier cities [15] - The company aims to expand its store count to approximately 70,000 in China and 10,000 to 15,000 in Southeast Asia, with potential growth in the Americas as well [15] 4. Financial Projections - The report provides detailed financial forecasts, projecting total revenue to reach 39.635 billion RMB by 2027, with a compound annual growth rate (CAGR) of approximately 11.33% from 2023 to 2027 [1] - The expected earnings per share (EPS) for 2025 is projected at 15.40 RMB, with a price-to-earnings (P/E) ratio of 23.81 [1]

Investment Rating - The report assigns a "Buy" rating to the company [3]. Core Insights - The report highlights the rapid growth potential of the domestic intelligent driving chip industry, with a significant increase in penetration rates expected in the coming years. The company is well-positioned to benefit from this trend [10][17]. - The company has a strong R&D team with extensive experience, which enhances its product development capabilities and market competitiveness [49]. - The report emphasizes the importance of collaboration with Tier 1 manufacturers and algorithm providers to drive commercialization and expand market presence [61]. Summary by Sections 1. Overall Dimension - The intelligent driving chip market is expected to grow rapidly due to increasing penetration rates driven by technological advancements, policy support, and rising consumer demand. The penetration rates for L2, L2.5, and L2.9 configurations are projected to increase significantly by 2030 [17][20]. - The report notes that only a few OEMs are likely to achieve self-developed chips due to high costs and complexities involved in chip development [29][33]. - Geopolitical factors are expected to drive the domestic market share of intelligent driving chips, with a focus on increasing localization [41][42]. 2. Product Dimension - The company is continuously iterating its products, with a focus on developing a mature ecosystem. The A1000 series has already achieved significant market penetration, and the upcoming C1200 family is expected to meet evolving automotive architecture needs [49][55]. - The C1200 family is designed to support central computing architectures and is expected to be commercially viable soon, with significant advancements in safety and performance [55][57]. 3. Ecosystem Dimension - The company positions itself as a Tier 2 supplier, collaborating with leading Tier 1 manufacturers and algorithm firms to enhance its market offerings. This strategy aims to provide OEMs with substantial value and differentiation in their intelligent driving solutions [61]. - The report discusses the limitations of a tightly integrated hardware-software model, as seen in the case of Mobileye, and suggests that a more flexible approach will be beneficial for OEMs [61]. 4. Growth Potential - The company is expanding its capabilities into the robotics sector, leveraging its automotive-grade chip technology to capture new market opportunities. The SesameX platform is a key initiative in this regard [10][27]. - Revenue forecasts indicate substantial growth, with expected revenues of 834 million in 2025, 1.38 billion in 2026, and 2.11 billion in 2027, reflecting year-on-year growth rates of 75.8%, 65.5%, and 52.8% respectively [8].

Investment Rating - The report assigns a rating of "Buy" for the company [4]. Core Insights - The report highlights a rich pipeline for the company in 2026, with expectations for significant clinical data readouts, including results for HER2 ADC, B7H3 ADC, and TROP2 ADC [12][19]. - The target price for the company has been raised to HKD 455.56 based on DCF valuation methods, reflecting increased confidence in the potential global sales peak for several ADC products [8][12]. Financial Summary - Total revenue is projected to grow from RMB 1,462 million in 2023 to RMB 2,516 million by 2027, with a notable increase of 23% in 2026 [3]. - Gross profit margin is expected to improve from 34% in 2025 to 51% in 2027, indicating a positive trend in profitability [3]. - Net profit is forecasted to decrease from RMB -757 million in 2025 to RMB -321 million in 2027, showing a gradual reduction in losses [3]. Pipeline Developments - HER2 ADC DB1303 is undergoing global registration clinical trials for multiple indications, with expected results in 2026 [12][11]. - B7H3 ADC DB1311 is anticipated to initiate a global Phase III clinical trial for 2L CRPC in 2026, following promising data from earlier studies [13][12]. - TROP2 ADC DB1305 is expected to demonstrate comparable efficacy to competitors in the market, with a focus on combination therapies [19][21]. Market Position - The company is positioned to compete effectively in the ADC market, with a strong emphasis on innovative therapies and strategic partnerships [12][19]. - The report notes the potential for the company's ADCs to become next-generation standard treatments in oncology, particularly in combination with other therapies [12][19].

Group 1 - The investment rating for the company is "Recommended" [3] - The core viewpoint of the report emphasizes that the company is positioned as a global source for new drug development, leveraging innovative gene editing technology and a robust antibody platform to drive growth [8][9] - The report highlights three main business segments: preclinical products and services, antibody platform, and clinical research organization (CRO) services, all of which are experiencing high growth due to favorable industry conditions [8][30] Group 2 - The company is expected to achieve significant revenue growth, with projected revenues of 9.80 billion RMB in 2024, 13.52 billion RMB in 2025, and 18.11 billion RMB in 2026, reflecting compound annual growth rates (CAGR) of 41.96% from 2019 to 2024 [2][30] - The net profit is forecasted to increase dramatically, with estimates of 34 million RMB in 2024, 155 million RMB in 2025, and 321 million RMB in 2026, indicating a CAGR of 362.6% from 2024 to 2025 [2][30] - The company has established a strong international presence, with overseas revenue accounting for 68% of total revenue in the first half of 2025, driven by a mature U.S. subsidiary and a diverse customer base [16][43] Group 3 - The report outlines the company's innovative gene editing technology as a key competitive advantage, enabling the development of customized animal models and enhancing the efficiency of drug development processes [48][51] - The antibody development business is expected to grow significantly, with revenues projected to reach 3.18 billion RMB by 2024, supported by a large library of antibody sequences and a flexible revenue model [39][40] - The company has a well-defined growth strategy, focusing on expanding its international market share and enhancing its service offerings to meet the evolving needs of pharmaceutical companies [8][30]

Investment Rating - The report assigns a "Buy" rating to the company with a current price of HKD 15.97 and a fair value of HKD 19.99 [4]. Core Insights - The company is the world's largest sports shoe manufacturer, driven by both manufacturing and retail operations, with a potential performance turnaround expected [1][9]. - The manufacturing business is expected to see revenue and profitability improvements due to various factors, including a recovery in order placements from brand clients and a favorable market environment in 2026 [9]. - The retail business is actively pursuing multi-channel and refined operations, which are anticipated to lead to a performance rebound [9]. Summary by Sections Company Overview - The company is the largest sports shoe manufacturer globally, with a market share based on annual production [14]. - It has a significant workforce of 285,500 employees, with 265,500 in manufacturing and 20,700 in retail [14]. - The company achieved a revenue of USD 8.182 billion in FY2024, reflecting a year-on-year growth of 3.7% [2][14]. Manufacturing Business - The manufacturing segment contributed 68.7% of total revenue and 85.2% of profit in FY2024, with revenues of USD 5.621 billion, up 11.1% year-on-year [17]. - The average selling price (ASP) for shoes was USD 20.25, down 5.1% year-on-year due to a higher concentration of high-end products in previous years [17]. - The company has a diversified production base across several countries, with significant output from Indonesia, Vietnam, and China [15][17]. Retail Business - The retail segment, operated through the subsidiary BaoSheng International, generated USD 2.561 billion in FY2024, a decrease of 9.5% year-on-year [24]. - The company is optimizing its store network, reducing the number of direct-operated stores to 3,448 while improving average store size [24]. - The retail business is expected to benefit from improved discount rates and effective inventory management [9]. Financial Projections - The company forecasts earnings per share (EPS) of USD 0.23, USD 0.26, and USD 0.28 for FY2025, FY2026, and FY2027, respectively [9]. - The report estimates a fair value of HKD 19.99 per share based on a sum-of-the-parts valuation method [9]. Market Performance - The company's stock price has shown significant volatility, with a historical increase of 2044.24% since its listing in 1992, although it has faced challenges in recent years due to external market conditions [46]. - The company’s price-to-earnings (P/E) ratio has fluctuated between 7 and 18 times, indicating a relatively low valuation compared to historical levels [46].

港股公司 证 券 研 究 报 告 康耐特光学（02276.HK）重大事项点评 强推（维持） 智能眼镜首次纳入国补，看好消费级产品渗 透率加速提升 事项： ❖ 25 年 12 月 30 日，国家发改委、财政部发布 2026 年国补政策，首次将智能眼 镜纳入补贴范围，补贴标准为 15%，单件补贴上限 500 元（单件产品售价不超 过 6000 元）。根据测算，智能眼镜价格超过 3300 元基本可以全额享受国补。 评论： 其他轻工Ⅲ 2025 年 12 月 31 日 | 目标价：63.63 | 港元 | | --- | --- | | 当前价：51.80 | 港元 | 华创证券研究所 证券分析师：刘一怡 邮箱：liuyiyi@hcyjs.com 执业编号：S0360524070003 联系人：周星宇 邮箱：zhouxingyu1@hcyjs.com ❖ 风险提示：智能眼镜发展不及预期、国内渠道拓展不及预期、行业竞争加剧。 [主要财务指标 Indicator_FinchinaSimpleHK] | | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | ...

研究报告 Research Report 31 Dec 2025 乐舒适 Softcare (2698 HK) 首次覆盖：聚焦新兴市场卫生用品赛道，本土化布局构筑竞争护城河 Focusing on the Hygiene Products Sector in Emerging Markets, Localized Deployment Builds Competitive Moat: Initiation [Table_yemei1] 观点聚焦 Investment Focus [Table_Info] 首次覆盖优于大市 Initiate with OUTPERFORM 评级 优于大市 OUTPERFORM 现价 HK$31.76 目标价 HK$40.50 HTI ESG 4.6-4.5-4.0 E-S-G: 0-5, (Please refer to the Appendix for ESG comments) 市值 HK$19.68bn / US$2.53bn 日交易额 (3 个月均值) US$9.76mn 发行股票数目 619.52mn 自由流通股 (%) 31% 1 年股价最高最低值 HK$33.54 ...

公司研究 心律管理业务重组合并，母公司亏损如期收窄中 2025 年 12 月 31 日 ——微创医疗（0853.HK）跟踪点评 要点 事件：公司近期公告 1）根据微创医疗集团会计政策其无法控制微创脑科学但仍 对其保持重大影响力，故终止合并微创脑科学，构成须予披露交易。2）微创心 通召开股东大会，审议通过并购微创心律管理有限公司的重大资产重组议案。此 次并购将推动微创医疗旗下结构性心脏病与心律管理两大核心业务板块的深度 整合。 点评： 治理结构改善注入新动能，出海业务成为核心增长引擎。公司治理层面，上实资 本旗下基金成为公司重要战略股东，有望在治理和业务发展方面注入新动能。公 司近期完成心律管理与结构性心脏病业务的重组，旨在打造综合心脏病平台，新 公司将融合微创心律管理的 AI 诊断及算法技术，与微创心通在结构性心脏病介 入治疗、输送系统及生物材料方面的技术积累，打造"结构性心脏病+心律管理 +心衰管理"一体化平台。公司亦公告终止合并微创脑科学，我们认为治理改善 持续推进中。同时，公司积极搭建全球通商业化平台，助力各业务板块产品出海， 25H1 出海业务收入已达 5,980 万美元，同比增长 57.3%，有效对 ...

上 市 公 司 公 司 研 究 / 公 司 深 ——稳健红利价值与成长性兼具的儿童电子学习领导者 财务数据及盈利预测 | 单位：百万美元 | 2024A | 2025A | 2026E | 2027E | 2028E | | --- | --- | --- | --- | --- | --- | | 营业收入 | 2,146 | 2,177 | 2,006 | 2,046 | 2,099 | | 收入增长率（%） | -4.3 | 1.5 | -7.9 | 2.0 | 2.6 | | 归属普通股东净利润 | 167 | 157 | 149 | 160 | 171 | | 归属普通股东净利润增 | 11.7 | -5.9 | -4.8 | 7.6 | 6.8 | | 长率（%） | | | | | | | 每股收益（美元） | 0.66 | 0.62 | 0.59 | 0.63 | 0.68 | | 毛利率（%） | 29.6 | 31.5 | 31.8 | 32.0 | 32.2 | | ROE（%） | 25.8 | 24.3 | 23.1 | 24.2 | 25.1 | | PE | 12 | 13 | ...

Investment Rating - The report gives a "Buy" rating for the company with a target price of HKD 18.1, representing a potential upside of 64% from the current price of HKD 10.98 [1]. Core Insights - The report emphasizes that the "takeaway war" has ignited a new journey in instant retail, termed "everything to home," highlighting the significant growth potential in the instant retail sector [4][21]. - The company is identified as the largest third-party instant delivery service platform in China, benefiting from the synergy of its independent third-party status and the broader ecosystem of SF Express [8][9]. - Financial performance shows a continuous improvement in profitability, with gross margins increasing from -23.3% in 2018 to 6.8% in 2024, and adjusted net profit margins improving from -36.4% to 0.93% over the same period [8][9]. Summary by Sections Instant Retail Market - Instant retail is characterized by online ordering and offline fulfillment, aiming to meet local immediate demands, with a projected market size of RMB 781 billion in 2024, growing at 20.15% year-on-year [4][38]. - The competition among major players like Meituan, Taobao, and JD has intensified, with significant subsidies driving daily order volumes to record highs [13][14][15]. - The report outlines three main service models in instant retail: front warehouses, comprehensive instant retail platforms, and store-warehouse integrated self-operated models [23][26][30]. Company Overview - The company is positioned as the leading third-party instant delivery service provider, leveraging the SF Express brand reputation and service capabilities to create a synergistic effect [8][9]. - The internal and external growth mechanisms, termed "dual flywheel," are driving significant revenue growth, with a forecasted increase in net profit from RMB 132 million in 2024 to RMB 707 million by 2027 [9][5]. Financial Projections - Revenue is expected to grow from RMB 15.746 billion in 2024 to RMB 32.731 billion by 2027, with a compound annual growth rate (CAGR) of 27.1% [5]. - The adjusted net profit is projected to reach RMB 8.1 billion by 2027, with a corresponding adjusted price-to-earnings (PE) ratio decreasing from 25 in 2025 to 11 in 2027 [9][5].